KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Regeneron Pharmaceuticals (REGN) Consolidated Net Income: 2009-2024

Historic Consolidated Net Income for Regeneron Pharmaceuticals (REGN) over the last 16 years, with Dec 2024 value amounting to $4.4 billion.

  • Regeneron Pharmaceuticals' Consolidated Net Income rose 8.91% to $1.5 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $4.6 billion, marking a year-over-year decrease of 1.64%. This contributed to the annual value of $4.4 billion for FY2024, which is 11.61% up from last year.
  • Latest data reveals that Regeneron Pharmaceuticals reported Consolidated Net Income of $4.4 billion as of FY2024, which was up 11.61% from $4.0 billion recorded in FY2023.
  • In the past 5 years, Regeneron Pharmaceuticals' Consolidated Net Income registered a high of $8.1 billion during FY2021, and its lowest value of $3.5 billion during FY2020.
  • Its 3-year average for Consolidated Net Income is $4.2 billion, with a median of $4.3 billion in 2022.
  • Its Consolidated Net Income has fluctuated over the past 5 years, first spiked by 129.86% in 2021, then slumped by 46.28% in 2022.
  • Over the past 5 years, Regeneron Pharmaceuticals' Consolidated Net Income (Yearly) stood at $3.5 billion in 2020, then surged by 129.86% to $8.1 billion in 2021, then plummeted by 46.28% to $4.3 billion in 2022, then declined by 8.87% to $4.0 billion in 2023, then climbed by 11.61% to $4.4 billion in 2024.